2022 Alzheimer's disease facts and figures
- PMID: 35289055
- DOI: 10.1002/alz.12638
2022 Alzheimer's disease facts and figures
Abstract
This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society. The Special Report discusses consumers' and primary care physicians' perspectives on awareness, diagnosis and treatment of mild cognitive impairment (MCI), including MCI due to Alzheimer's disease. An estimated 6.5 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Official death certificates recorded 121,499 deaths from AD in 2019, the latest year for which data are available. Alzheimer's disease was officially listed as the sixth-leading cause of death in the United States in 2019 and the seventh-leading cause of death in 2020 and 2021, when COVID-19 entered the ranks of the top ten causes of death. Alzheimer's remains the fifth-leading cause of death among Americans age 65 and older. Between 2000 and 2019, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 145%. More than 11 million family members and other unpaid caregivers provided an estimated 16 billion hours of care to people with Alzheimer's or other dementias in 2021. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at $271.6 billion in 2021. Its costs, however, extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes - costs that have been aggravated by COVID-19. Members of the dementia care workforce have also been affected by COVID-19. As essential care workers, some have opted to change jobs to protect their own health and the health of their families. However, this occurs at a time when more members of the dementia care workforce are needed. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are almost three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 22 times as great. Total payments in 2022 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $321 billion. A recent survey commissioned by the Alzheimer's Association revealed several barriers to consumers' understanding of MCI. The survey showed low awareness of MCI among Americans, a reluctance among Americans to see their doctor after noticing MCI symptoms, and persistent challenges for primary care physicians in diagnosing MCI. Survey results indicate the need to improve MCI awareness and diagnosis, especially in underserved communities, and to encourage greater participation in MCI-related clinical trials.
Keywords: Alzheimer's dementia; Alzheimer's disease; Biomarkers; COVID-19; Caregivers; Dementia; Dementia workforce; Diagnostic criteria; Family caregiver; Health care costs; Health care expenditures; Health care professional; Incidence; Long-term care costs; MCI due to Alzheimer's disease; Medicaid spending; Medicare spending; Mild cognitive impairment; Morbidity; Mortality; Prevalence; Primary care physician; Risk factors; Spouse caregiver.
© 2022 the Alzheimer's Association.
Similar articles
-
2024 Alzheimer's disease facts and figures.Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30. Alzheimers Dement. 2024. PMID: 38689398 Free PMC article.
-
2023 Alzheimer's disease facts and figures.Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14. Alzheimers Dement. 2023. PMID: 36918389
-
2021 Alzheimer's disease facts and figures.Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23. Alzheimers Dement. 2021. PMID: 33756057
-
Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. PMID: 28876770 Free Books & Documents. Review.
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
Cited by
-
Bayesian genome-wide TWAS with reference transcriptomic data of brain and blood tissues identified 141 risk genes for Alzheimer's disease dementia.Alzheimers Res Ther. 2024 Jun 1;16(1):120. doi: 10.1186/s13195-024-01488-7. Alzheimers Res Ther. 2024. PMID: 38824563 Free PMC article.
-
Bidirectional two-sample Mendelian randomization analyses support causal relationships between structural and diffusion imaging-derived phenotypes and the risk of major neurodegenerative diseases.Transl Psychiatry. 2024 May 28;14(1):215. doi: 10.1038/s41398-024-02939-3. Transl Psychiatry. 2024. PMID: 38806463 Free PMC article.
-
From Alzheimer's Disease to Anxiety, Epilepsy to Schizophrenia: A Comprehensive Dive Into Neuro-Psychiatric Disorders.Cureus. 2024 Apr 22;16(4):e58776. doi: 10.7759/cureus.58776. eCollection 2024 Apr. Cureus. 2024. PMID: 38784315 Free PMC article. Review.
-
Assessment of cognitive games to improve the quality of life of Parkinson's and Alzheimer's patients.Digit Health. 2024 May 22;10:20552076241254733. doi: 10.1177/20552076241254733. eCollection 2024 Jan-Dec. Digit Health. 2024. PMID: 38784051 Free PMC article.
-
Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients.Commun Med (Lond). 2024 May 23;4(1):99. doi: 10.1038/s43856-024-00527-6. Commun Med (Lond). 2024. PMID: 38783011 Free PMC article.
References
REFERENCES
-
- Quiroz YT, Zetterberg H, Reiman EM, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional and longitudinal cohort study. Lancet Neuro 2020;19(6):513-521.
-
- Barthelemy N, Joseph-Mathurin N, Gordon BA, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med 2020;26:398-407.
-
- Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013;12(4):357-567.
-
- Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 2012;11(2):1048-1056.
-
- Jack CR, Lowe VJ, Weigand SD, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials